Sarah Faubel
Concepts (457)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acute Kidney Injury | 87 | 2026 | 865 | 15.520 |
Why?
| | Ischemia | 13 | 2026 | 421 | 3.120 |
Why?
| | Kidney | 26 | 2026 | 1495 | 2.950 |
Why?
| | Interleukin-6 | 17 | 2023 | 780 | 2.600 |
Why?
| | Reperfusion Injury | 8 | 2023 | 300 | 2.190 |
Why?
| | Energy Metabolism | 6 | 2026 | 935 | 2.100 |
Why?
| | Acute Lung Injury | 6 | 2021 | 303 | 1.910 |
Why?
| | Sepsis | 10 | 2025 | 640 | 1.880 |
Why?
| | Mice, Inbred C57BL | 39 | 2026 | 5992 | 1.870 |
Why?
| | Metabolome | 6 | 2026 | 384 | 1.850 |
Why?
| | Azotemia | 2 | 2026 | 13 | 1.740 |
Why?
| | Lung Injury | 6 | 2017 | 237 | 1.700 |
Why?
| | Metabolomics | 5 | 2026 | 727 | 1.530 |
Why?
| | Renal Replacement Therapy | 10 | 2023 | 100 | 1.500 |
Why?
| | Cardiac Surgical Procedures | 10 | 2020 | 609 | 1.470 |
Why?
| | Amino Acids | 2 | 2026 | 521 | 1.420 |
Why?
| | Nephrectomy | 7 | 2021 | 158 | 1.410 |
Why?
| | Water-Electrolyte Imbalance | 5 | 2020 | 42 | 1.400 |
Why?
| | Cardio-Renal Syndrome | 2 | 2023 | 18 | 1.350 |
Why?
| | Interleukin-10 | 6 | 2017 | 309 | 1.160 |
Why?
| | Cytokines | 14 | 2021 | 2061 | 1.160 |
Why?
| | Creatinine | 12 | 2020 | 506 | 1.070 |
Why?
| | Mice | 49 | 2026 | 18339 | 1.050 |
Why?
| | Disease Models, Animal | 21 | 2026 | 4557 | 1.040 |
Why?
| | Biomarkers | 20 | 2026 | 4271 | 1.030 |
Why?
| | Pneumonia | 4 | 2021 | 631 | 0.990 |
Why?
| | Euthyroid Sick Syndromes | 1 | 2026 | 6 | 0.970 |
Why?
| | Caspase 1 | 12 | 2014 | 148 | 0.960 |
Why?
| | Interleukin-18 | 11 | 2019 | 235 | 0.950 |
Why?
| | Glutathione | 2 | 2026 | 375 | 0.940 |
Why?
| | Thyrotropin | 1 | 2026 | 118 | 0.930 |
Why?
| | Thyroid Gland | 1 | 2026 | 88 | 0.920 |
Why?
| | Oxidative Stress | 3 | 2024 | 1339 | 0.910 |
Why?
| | Kidney Failure, Chronic | 5 | 2025 | 598 | 0.880 |
Why?
| | Postoperative Complications | 9 | 2020 | 2919 | 0.860 |
Why?
| | Animals | 59 | 2026 | 38058 | 0.820 |
Why?
| | Exploratory Behavior | 1 | 2024 | 86 | 0.820 |
Why?
| | Lipocalins | 3 | 2019 | 35 | 0.810 |
Why?
| | Lipocalin-2 | 7 | 2023 | 79 | 0.770 |
Why?
| | Clinical Clerkship | 1 | 2024 | 111 | 0.750 |
Why?
| | Body Fluids | 2 | 2020 | 70 | 0.730 |
Why?
| | Tissue Inhibitor of Metalloproteinase-2 | 4 | 2019 | 14 | 0.710 |
Why?
| | Cardiopulmonary Bypass | 3 | 2019 | 221 | 0.680 |
Why?
| | Glomerular Filtration Rate | 7 | 2026 | 760 | 0.680 |
Why?
| | Kidney Function Tests | 2 | 2019 | 157 | 0.670 |
Why?
| | Insulin-Like Growth Factor Binding Proteins | 3 | 2018 | 26 | 0.670 |
Why?
| | Nephrologists | 2 | 2017 | 14 | 0.660 |
Why?
| | Urokinase-Type Plasminogen Activator | 1 | 2020 | 24 | 0.650 |
Why?
| | Male | 60 | 2026 | 72315 | 0.640 |
Why?
| | Hospital Mortality | 9 | 2020 | 1030 | 0.630 |
Why?
| | Heart Diseases | 2 | 2023 | 349 | 0.630 |
Why?
| | Intensive Care Units | 8 | 2021 | 916 | 0.620 |
Why?
| | Cisplatin | 7 | 2016 | 334 | 0.620 |
Why?
| | Liver | 3 | 2024 | 1887 | 0.610 |
Why?
| | Systemic Inflammatory Response Syndrome | 2 | 2017 | 96 | 0.580 |
Why?
| | Peritoneal Dialysis | 2 | 2018 | 100 | 0.580 |
Why?
| | Heart Failure, Diastolic | 1 | 2019 | 24 | 0.580 |
Why?
| | Critical Illness | 9 | 2023 | 891 | 0.580 |
Why?
| | Adenosine Triphosphate | 2 | 2021 | 498 | 0.570 |
Why?
| | Renal Dialysis | 6 | 2021 | 462 | 0.570 |
Why?
| | Pulmonary Edema | 1 | 2019 | 106 | 0.560 |
Why?
| | Chemokine CXCL1 | 6 | 2012 | 76 | 0.540 |
Why?
| | Kidney Diseases | 5 | 2021 | 427 | 0.530 |
Why?
| | Humans | 71 | 2026 | 144759 | 0.530 |
Why?
| | Kidney Tubular Necrosis, Acute | 5 | 2015 | 26 | 0.520 |
Why?
| | Interleukin-1beta | 6 | 2014 | 395 | 0.500 |
Why?
| | Lung | 7 | 2023 | 4109 | 0.500 |
Why?
| | Nephrology | 3 | 2016 | 60 | 0.480 |
Why?
| | CD4-Positive T-Lymphocytes | 3 | 2017 | 1129 | 0.480 |
Why?
| | Proteinuria | 3 | 2019 | 102 | 0.480 |
Why?
| | Peroxidase | 6 | 2017 | 168 | 0.470 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2016 | 69 | 0.470 |
Why?
| | Hyperkalemia | 1 | 2016 | 35 | 0.460 |
Why?
| | Muscle, Skeletal | 1 | 2026 | 1795 | 0.460 |
Why?
| | Models, Animal | 1 | 2017 | 392 | 0.450 |
Why?
| | Caspase Inhibitors | 7 | 2014 | 81 | 0.450 |
Why?
| | Containment of Biohazards | 1 | 2015 | 21 | 0.440 |
Why?
| | Acidosis | 1 | 2016 | 105 | 0.440 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2015 | 20 | 0.440 |
Why?
| | Losartan | 1 | 2014 | 13 | 0.430 |
Why?
| | Critical Care | 4 | 2021 | 695 | 0.430 |
Why?
| | Lisinopril | 1 | 2014 | 15 | 0.430 |
Why?
| | Neutrophil Infiltration | 4 | 2012 | 104 | 0.420 |
Why?
| | Angiotensin II Type 1 Receptor Blockers | 1 | 2014 | 38 | 0.420 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2015 | 81 | 0.420 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2013 | 1217 | 0.410 |
Why?
| | Chlorides | 3 | 2020 | 142 | 0.410 |
Why?
| | Thrombocytopenia | 3 | 2021 | 205 | 0.410 |
Why?
| | Early Medical Intervention | 1 | 2013 | 61 | 0.390 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2014 | 221 | 0.390 |
Why?
| | Respiration, Artificial | 4 | 2018 | 708 | 0.390 |
Why?
| | Ultrasonography, Doppler | 1 | 2013 | 126 | 0.380 |
Why?
| | Apoptosis | 10 | 2019 | 2430 | 0.380 |
Why?
| | Severity of Illness Index | 5 | 2014 | 2925 | 0.370 |
Why?
| | Interleukin-8 | 2 | 2013 | 271 | 0.360 |
Why?
| | Acute-Phase Proteins | 3 | 2019 | 67 | 0.350 |
Why?
| | Kidney Tubules, Proximal | 3 | 2014 | 130 | 0.350 |
Why?
| | Developing Countries | 1 | 2013 | 318 | 0.340 |
Why?
| | Splenectomy | 1 | 2011 | 65 | 0.340 |
Why?
| | Diagnostic Imaging | 1 | 2014 | 338 | 0.330 |
Why?
| | Prospective Studies | 6 | 2026 | 7990 | 0.310 |
Why?
| | Polycystic Kidney Diseases | 3 | 2025 | 71 | 0.290 |
Why?
| | Multiple Organ Failure | 1 | 2009 | 124 | 0.290 |
Why?
| | Hepatocytes | 2 | 2020 | 223 | 0.290 |
Why?
| | Mice, Knockout | 10 | 2025 | 3121 | 0.280 |
Why?
| | Macrophages, Alveolar | 1 | 2011 | 368 | 0.280 |
Why?
| | Uremia | 1 | 2008 | 15 | 0.280 |
Why?
| | Heart Failure | 3 | 2024 | 2323 | 0.280 |
Why?
| | Female | 31 | 2026 | 78271 | 0.280 |
Why?
| | Antibodies, Monoclonal | 2 | 2013 | 1519 | 0.270 |
Why?
| | Inflammation Mediators | 6 | 2021 | 509 | 0.270 |
Why?
| | Antineoplastic Agents | 5 | 2016 | 2194 | 0.260 |
Why?
| | Retrospective Studies | 15 | 2025 | 17066 | 0.250 |
Why?
| | Time Factors | 8 | 2019 | 7173 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2019 | 1720 | 0.250 |
Why?
| | Endotoxins | 3 | 2013 | 221 | 0.250 |
Why?
| | Thyroid Function Tests | 1 | 2026 | 18 | 0.240 |
Why?
| | Endothelial Cells | 6 | 2019 | 869 | 0.240 |
Why?
| | Triiodothyronine | 1 | 2026 | 54 | 0.240 |
Why?
| | Inflammation | 5 | 2019 | 2878 | 0.240 |
Why?
| | Thyroxine | 1 | 2026 | 64 | 0.240 |
Why?
| | Lymphocyte Depletion | 2 | 2005 | 132 | 0.240 |
Why?
| | Blood Urea Nitrogen | 4 | 2013 | 53 | 0.230 |
Why?
| | Respiratory Insufficiency | 2 | 2011 | 326 | 0.230 |
Why?
| | Delayed Graft Function | 1 | 2005 | 46 | 0.230 |
Why?
| | Necrosis | 4 | 2014 | 244 | 0.220 |
Why?
| | Lung Diseases | 2 | 2009 | 787 | 0.220 |
Why?
| | Caspases | 7 | 2013 | 232 | 0.220 |
Why?
| | Lymphoid Tissue | 1 | 2025 | 80 | 0.220 |
Why?
| | Middle Aged | 16 | 2026 | 35875 | 0.210 |
Why?
| | Autophagy | 2 | 2021 | 286 | 0.210 |
Why?
| | Clinical Trials as Topic | 4 | 2016 | 1053 | 0.210 |
Why?
| | Macrophages | 6 | 2021 | 1511 | 0.210 |
Why?
| | Risk Factors | 12 | 2021 | 10779 | 0.210 |
Why?
| | Caspase 3 | 9 | 2011 | 238 | 0.210 |
Why?
| | Hepcidins | 1 | 2023 | 22 | 0.200 |
Why?
| | Acute-Phase Reaction | 1 | 2023 | 37 | 0.200 |
Why?
| | Infant, Newborn | 7 | 2023 | 6429 | 0.200 |
Why?
| | Furosemide | 1 | 2023 | 37 | 0.200 |
Why?
| | Predictive Value of Tests | 3 | 2014 | 2115 | 0.200 |
Why?
| | Cell Membrane | 1 | 2007 | 706 | 0.190 |
Why?
| | Intensive Care Units, Pediatric | 4 | 2020 | 285 | 0.190 |
Why?
| | Aged | 11 | 2026 | 25913 | 0.190 |
Why?
| | Infant | 6 | 2018 | 10034 | 0.180 |
Why?
| | Glycolysis | 1 | 2024 | 339 | 0.180 |
Why?
| | Spleen | 2 | 2017 | 508 | 0.180 |
Why?
| | Capillary Leak Syndrome | 2 | 2012 | 12 | 0.180 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2021 | 17 | 0.180 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2021 | 20 | 0.180 |
Why?
| | Nephritis | 1 | 2021 | 22 | 0.180 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2025 | 449 | 0.180 |
Why?
| | Ureteral Obstruction | 1 | 2021 | 62 | 0.170 |
Why?
| | Child, Preschool | 7 | 2020 | 11787 | 0.170 |
Why?
| | Autophagy-Related Proteins | 1 | 2021 | 46 | 0.170 |
Why?
| | Kidney Tubules | 3 | 2012 | 117 | 0.170 |
Why?
| | Stroke Volume | 1 | 2024 | 651 | 0.170 |
Why?
| | Receptors, Urokinase Plasminogen Activator | 1 | 2020 | 11 | 0.160 |
Why?
| | Propensity Score | 2 | 2019 | 367 | 0.160 |
Why?
| | Evidence-Based Medicine | 1 | 2024 | 732 | 0.160 |
Why?
| | Fibrosis | 3 | 2021 | 548 | 0.160 |
Why?
| | Drug Delivery Systems | 3 | 2016 | 380 | 0.160 |
Why?
| | Chemokine CX3CL1 | 3 | 2011 | 25 | 0.160 |
Why?
| | Diagnosis, Differential | 2 | 2015 | 1489 | 0.160 |
Why?
| | Learning | 1 | 2024 | 452 | 0.150 |
Why?
| | Dialysis Solutions | 1 | 2019 | 23 | 0.150 |
Why?
| | Amino Acid Chloromethyl Ketones | 4 | 2014 | 24 | 0.150 |
Why?
| | Students, Medical | 1 | 2024 | 375 | 0.150 |
Why?
| | Sex Factors | 3 | 2022 | 2112 | 0.150 |
Why?
| | Kidney Transplantation | 1 | 2005 | 704 | 0.140 |
Why?
| | Biopsy, Needle | 1 | 2019 | 183 | 0.140 |
Why?
| | Norwood Procedures | 1 | 2018 | 29 | 0.140 |
Why?
| | Random Allocation | 1 | 2019 | 363 | 0.140 |
Why?
| | Delivery of Health Care | 2 | 2015 | 947 | 0.140 |
Why?
| | Milrinone | 1 | 2018 | 26 | 0.140 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2023 | 410 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2016 | 1560 | 0.130 |
Why?
| | Cohort Studies | 3 | 2025 | 5960 | 0.130 |
Why?
| | History, 20th Century | 1 | 2019 | 325 | 0.130 |
Why?
| | Immunohistochemistry | 3 | 2019 | 1716 | 0.130 |
Why?
| | Hypoplastic Left Heart Syndrome | 1 | 2018 | 120 | 0.130 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2015 | 653 | 0.130 |
Why?
| | Recovery of Function | 2 | 2019 | 707 | 0.130 |
Why?
| | Cell Line | 5 | 2021 | 2882 | 0.130 |
Why?
| | Curriculum | 1 | 2024 | 1059 | 0.130 |
Why?
| | Hyaluronic Acid | 2 | 2016 | 208 | 0.130 |
Why?
| | Feasibility Studies | 3 | 2017 | 1095 | 0.130 |
Why?
| | Cell Cycle Checkpoints | 1 | 2017 | 99 | 0.120 |
Why?
| | Length of Stay | 5 | 2020 | 1337 | 0.120 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 257 | 0.120 |
Why?
| | CD4 Antigens | 1 | 2017 | 139 | 0.120 |
Why?
| | Prognosis | 3 | 2014 | 4282 | 0.120 |
Why?
| | Postoperative Care | 1 | 2018 | 288 | 0.120 |
Why?
| | Mice, Mutant Strains | 3 | 2005 | 299 | 0.120 |
Why?
| | Quinolines | 3 | 2014 | 193 | 0.120 |
Why?
| | Survival Rate | 4 | 2018 | 2089 | 0.120 |
Why?
| | Blood Pressure | 2 | 2022 | 1769 | 0.120 |
Why?
| | Endotoxemia | 2 | 2008 | 87 | 0.120 |
Why?
| | Clinical Competence | 1 | 2024 | 1244 | 0.120 |
Why?
| | Disease Progression | 4 | 2019 | 2847 | 0.120 |
Why?
| | Hemodialysis Units, Hospital | 1 | 2015 | 5 | 0.120 |
Why?
| | Echocardiography | 1 | 2019 | 652 | 0.120 |
Why?
| | Risk Assessment | 4 | 2019 | 3671 | 0.110 |
Why?
| | Contraindications | 1 | 2015 | 91 | 0.110 |
Why?
| | Developed Countries | 1 | 2015 | 38 | 0.110 |
Why?
| | Patient Isolation | 1 | 2015 | 20 | 0.110 |
Why?
| | Heart | 1 | 2019 | 636 | 0.110 |
Why?
| | Transforming Growth Factor beta | 2 | 2015 | 479 | 0.110 |
Why?
| | Neutrophils | 3 | 2007 | 1134 | 0.110 |
Why?
| | Africa | 1 | 2015 | 116 | 0.110 |
Why?
| | Equipment Contamination | 1 | 2015 | 71 | 0.110 |
Why?
| | Mice, Transgenic | 5 | 2011 | 2182 | 0.110 |
Why?
| | Interleukin-1alpha | 1 | 2014 | 57 | 0.110 |
Why?
| | Nitric Oxide | 3 | 2008 | 897 | 0.100 |
Why?
| | Delayed-Action Preparations | 1 | 2015 | 183 | 0.100 |
Why?
| | Ebolavirus | 1 | 2015 | 89 | 0.100 |
Why?
| | Up-Regulation | 1 | 2017 | 851 | 0.100 |
Why?
| | Travel | 1 | 2015 | 136 | 0.100 |
Why?
| | Myocardium | 1 | 2019 | 939 | 0.100 |
Why?
| | Antibodies | 3 | 2012 | 401 | 0.100 |
Why?
| | Calpain | 4 | 2006 | 61 | 0.100 |
Why?
| | Kinetics | 1 | 2017 | 1627 | 0.100 |
Why?
| | Oncogene Proteins | 1 | 2013 | 61 | 0.100 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2013 | 636 | 0.100 |
Why?
| | Cardiovascular Diseases | 2 | 2019 | 2168 | 0.100 |
Why?
| | Interleukins | 2 | 2011 | 248 | 0.100 |
Why?
| | Quality Improvement | 2 | 2019 | 1289 | 0.100 |
Why?
| | Anticoagulants | 2 | 2015 | 722 | 0.100 |
Why?
| | Receptors, Interleukin-8B | 1 | 2012 | 23 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 3 | 2011 | 851 | 0.090 |
Why?
| | Age Factors | 3 | 2018 | 3333 | 0.090 |
Why?
| | Albumins | 1 | 2013 | 118 | 0.090 |
Why?
| | Workload | 1 | 2014 | 170 | 0.090 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2017 | 365 | 0.090 |
Why?
| | Podocytes | 1 | 2013 | 80 | 0.090 |
Why?
| | Endocytosis | 1 | 2013 | 168 | 0.090 |
Why?
| | Hydrogels | 2 | 2016 | 700 | 0.090 |
Why?
| | Adolescent | 7 | 2020 | 22428 | 0.090 |
Why?
| | Complement Factor B | 1 | 2012 | 106 | 0.090 |
Why?
| | Disease Outbreaks | 1 | 2015 | 422 | 0.090 |
Why?
| | Drug Therapy, Combination | 1 | 2014 | 1047 | 0.090 |
Why?
| | Child | 7 | 2020 | 22633 | 0.090 |
Why?
| | Flow Cytometry | 3 | 2011 | 1173 | 0.090 |
Why?
| | Toll-Like Receptor 2 | 1 | 2012 | 126 | 0.090 |
Why?
| | Radiography | 1 | 2014 | 844 | 0.090 |
Why?
| | Anti-Inflammatory Agents | 1 | 2015 | 474 | 0.090 |
Why?
| | B-Lymphocytes | 1 | 2017 | 876 | 0.090 |
Why?
| | Trachea | 1 | 2013 | 261 | 0.080 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2008 | 162 | 0.080 |
Why?
| | Caspase 8 | 3 | 2005 | 47 | 0.080 |
Why?
| | Cold Temperature | 3 | 2011 | 209 | 0.080 |
Why?
| | MicroRNAs | 1 | 2017 | 701 | 0.080 |
Why?
| | Chemokines | 2 | 2008 | 218 | 0.080 |
Why?
| | Ambulatory Care | 1 | 2015 | 600 | 0.080 |
Why?
| | Continuity of Patient Care | 1 | 2013 | 291 | 0.080 |
Why?
| | Analysis of Variance | 1 | 2013 | 1306 | 0.080 |
Why?
| | Patient Selection | 4 | 2019 | 719 | 0.080 |
Why?
| | Organ Preservation | 1 | 2011 | 130 | 0.080 |
Why?
| | Immunoblotting | 3 | 2005 | 300 | 0.080 |
Why?
| | Toll-Like Receptor 4 | 1 | 2012 | 276 | 0.080 |
Why?
| | L-Lactate Dehydrogenase | 2 | 2007 | 115 | 0.080 |
Why?
| | Heart Defects, Congenital | 1 | 2018 | 914 | 0.080 |
Why?
| | Ultrasonography | 1 | 2014 | 770 | 0.080 |
Why?
| | Bleomycin | 1 | 2011 | 253 | 0.080 |
Why?
| | Proto-Oncogene Proteins | 1 | 2013 | 623 | 0.070 |
Why?
| | Research Design | 1 | 2015 | 1135 | 0.070 |
Why?
| | Survivors | 1 | 2013 | 520 | 0.070 |
Why?
| | Complement Activation | 1 | 2012 | 411 | 0.070 |
Why?
| | Patient Care Team | 1 | 2015 | 689 | 0.070 |
Why?
| | Monocytes | 1 | 2011 | 538 | 0.070 |
Why?
| | NF-kappa B | 2 | 2013 | 661 | 0.070 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 2 | 2019 | 41 | 0.070 |
Why?
| | Macrophages, Peritoneal | 1 | 2009 | 89 | 0.070 |
Why?
| | Dendritic Cells | 1 | 2012 | 499 | 0.070 |
Why?
| | Fluid Therapy | 1 | 2009 | 147 | 0.070 |
Why?
| | CD11b Antigen | 4 | 2009 | 60 | 0.070 |
Why?
| | Caspase 9 | 2 | 2004 | 55 | 0.070 |
Why?
| | Urothelium | 1 | 2008 | 33 | 0.070 |
Why?
| | Capillary Permeability | 1 | 2008 | 134 | 0.070 |
Why?
| | Receptors, Chemokine | 1 | 2007 | 47 | 0.070 |
Why?
| | Endpoint Determination | 3 | 2012 | 83 | 0.070 |
Why?
| | Cysteine Proteinase Inhibitors | 2 | 2004 | 50 | 0.060 |
Why?
| | Case-Control Studies | 2 | 2019 | 3604 | 0.060 |
Why?
| | Pulmonary Fibrosis | 1 | 2011 | 395 | 0.060 |
Why?
| | Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 109 | 0.060 |
Why?
| | Water-Electrolyte Balance | 2 | 2018 | 36 | 0.060 |
Why?
| | RNA, Messenger | 4 | 2009 | 2832 | 0.060 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2008 | 381 | 0.060 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2008 | 380 | 0.060 |
Why?
| | Mass Screening | 1 | 2015 | 1347 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2008 | 436 | 0.060 |
Why?
| | Cell Hypoxia | 1 | 2007 | 247 | 0.060 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 2005 | 11 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1486 | 0.060 |
Why?
| | Autophagy-Related Protein 7 | 1 | 2025 | 13 | 0.060 |
Why?
| | Liver Transplantation | 1 | 2013 | 823 | 0.060 |
Why?
| | Enzyme Inhibitors | 2 | 2008 | 824 | 0.060 |
Why?
| | Regulatory-Associated Protein of mTOR | 1 | 2025 | 24 | 0.060 |
Why?
| | Albuminuria | 2 | 2019 | 190 | 0.060 |
Why?
| | Survival Analysis | 2 | 2019 | 1382 | 0.060 |
Why?
| | Odds Ratio | 2 | 2018 | 1075 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2019 | 11679 | 0.050 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 2 | 2005 | 235 | 0.050 |
Why?
| | Insulin Resistance | 1 | 2013 | 1241 | 0.050 |
Why?
| | Adult | 7 | 2021 | 40449 | 0.050 |
Why?
| | Pilot Projects | 3 | 2018 | 1886 | 0.050 |
Why?
| | Cytosol | 1 | 2004 | 227 | 0.050 |
Why?
| | Rats | 4 | 2023 | 5597 | 0.050 |
Why?
| | Myocardial Ischemia | 1 | 2005 | 285 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2013 | 2730 | 0.050 |
Why?
| | Young Adult | 3 | 2017 | 14105 | 0.050 |
Why?
| | Colorado | 3 | 2019 | 4564 | 0.050 |
Why?
| | Cell Proliferation | 2 | 2007 | 2496 | 0.050 |
Why?
| | Contrast Media | 2 | 2016 | 488 | 0.050 |
Why?
| | Gene Expression Regulation | 2 | 2013 | 2608 | 0.050 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2021 | 34 | 0.040 |
Why?
| | Sample Size | 2 | 2012 | 123 | 0.040 |
Why?
| | Brain Ischemia | 1 | 2005 | 358 | 0.040 |
Why?
| | Comorbidity | 2 | 2019 | 1658 | 0.040 |
Why?
| | Kidney Glomerulus | 2 | 2013 | 128 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3863 | 0.040 |
Why?
| | Statistics as Topic | 2 | 2012 | 284 | 0.040 |
Why?
| | Cells, Cultured | 4 | 2012 | 4154 | 0.040 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 94 | 0.040 |
Why?
| | Platelet Count | 1 | 2021 | 96 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2021 | 63 | 0.040 |
Why?
| | United States | 3 | 2015 | 15966 | 0.040 |
Why?
| | Mice, Inbred BALB C | 2 | 2015 | 1253 | 0.040 |
Why?
| | Stroke | 2 | 2019 | 1256 | 0.040 |
Why?
| | Lysosomes | 1 | 2021 | 128 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2023 | 902 | 0.040 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2023 | 557 | 0.040 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2021 | 173 | 0.040 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2021 | 139 | 0.040 |
Why?
| | Leukocytes | 1 | 2021 | 295 | 0.040 |
Why?
| | Bicarbonates | 1 | 2020 | 45 | 0.040 |
Why?
| | Matched-Pair Analysis | 1 | 2019 | 37 | 0.040 |
Why?
| | Obesity | 1 | 2013 | 3077 | 0.040 |
Why?
| | Trefoil Factor-3 | 1 | 2019 | 5 | 0.040 |
Why?
| | Netrin-1 | 1 | 2019 | 15 | 0.040 |
Why?
| | Clusterin | 1 | 2019 | 11 | 0.040 |
Why?
| | beta 2-Microglobulin | 1 | 2019 | 47 | 0.040 |
Why?
| | Hospitals, University | 1 | 2019 | 176 | 0.040 |
Why?
| | Cystatin C | 1 | 2019 | 65 | 0.040 |
Why?
| | Incidence | 2 | 2018 | 2879 | 0.040 |
Why?
| | Age Distribution | 1 | 2019 | 403 | 0.040 |
Why?
| | Sex Distribution | 1 | 2019 | 386 | 0.040 |
Why?
| | Fatty Acid-Binding Proteins | 1 | 2019 | 79 | 0.040 |
Why?
| | Models, Theoretical | 1 | 2022 | 582 | 0.030 |
Why?
| | Signal Transduction | 3 | 2021 | 5226 | 0.030 |
Why?
| | Substance Abuse, Intravenous | 1 | 2019 | 128 | 0.030 |
Why?
| | Exosomes | 1 | 2019 | 104 | 0.030 |
Why?
| | Cardiotonic Agents | 1 | 2018 | 95 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 779 | 0.030 |
Why?
| | Multicenter Studies as Topic | 1 | 2019 | 405 | 0.030 |
Why?
| | Zebrafish | 1 | 2022 | 528 | 0.030 |
Why?
| | Hospitalization | 2 | 2018 | 2433 | 0.030 |
Why?
| | Immunocompromised Host | 1 | 2018 | 201 | 0.030 |
Why?
| | Thoracic Surgery | 1 | 2018 | 144 | 0.030 |
Why?
| | Decision Trees | 1 | 2016 | 81 | 0.030 |
Why?
| | Free Radical Scavengers | 1 | 2015 | 82 | 0.030 |
Why?
| | Caspase 2 | 2 | 2006 | 12 | 0.030 |
Why?
| | Sodium Bicarbonate | 1 | 2015 | 47 | 0.030 |
Why?
| | Heterozygote | 2 | 2007 | 315 | 0.030 |
Why?
| | Colitis, Ulcerative | 1 | 2017 | 147 | 0.030 |
Why?
| | Acetylcysteine | 1 | 2015 | 139 | 0.030 |
Why?
| | In Situ Nick-End Labeling | 2 | 2005 | 121 | 0.030 |
Why?
| | Interleukin-1 | 2 | 2012 | 961 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2016 | 249 | 0.030 |
Why?
| | Reimbursement Mechanisms | 1 | 2015 | 80 | 0.030 |
Why?
| | Erythropoietin | 1 | 2015 | 100 | 0.030 |
Why?
| | Protective Agents | 1 | 2014 | 42 | 0.030 |
Why?
| | Antioxidants | 2 | 2008 | 549 | 0.030 |
Why?
| | Interprofessional Relations | 1 | 2016 | 281 | 0.030 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 1 | 2017 | 248 | 0.030 |
Why?
| | Lipopolysaccharides | 1 | 2017 | 863 | 0.020 |
Why?
| | Phenotype | 1 | 2021 | 3162 | 0.020 |
Why?
| | Crohn Disease | 1 | 2017 | 260 | 0.020 |
Why?
| | Smoking | 1 | 2019 | 1472 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2017 | 8265 | 0.020 |
Why?
| | Clodronic Acid | 1 | 2012 | 19 | 0.020 |
Why?
| | Health Policy | 1 | 2015 | 400 | 0.020 |
Why?
| | Diphtheria Toxin | 1 | 2012 | 65 | 0.020 |
Why?
| | Cost of Illness | 1 | 2014 | 321 | 0.020 |
Why?
| | Chemokine CCL2 | 1 | 2012 | 115 | 0.020 |
Why?
| | Diet, High-Fat | 1 | 2013 | 261 | 0.020 |
Why?
| | Lung Compliance | 1 | 2011 | 42 | 0.020 |
Why?
| | Interleukin-33 | 1 | 2011 | 45 | 0.020 |
Why?
| | Trauma Severity Indices | 1 | 2011 | 112 | 0.020 |
Why?
| | Postoperative Period | 1 | 2012 | 354 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 1098 | 0.020 |
Why?
| | Global Health | 1 | 2014 | 401 | 0.020 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2012 | 161 | 0.020 |
Why?
| | Informed Consent | 1 | 2012 | 198 | 0.020 |
Why?
| | Immunotherapy | 1 | 2015 | 653 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2014 | 589 | 0.020 |
Why?
| | Medicare | 1 | 2015 | 886 | 0.020 |
Why?
| | Algorithms | 1 | 2017 | 1837 | 0.020 |
Why?
| | Body Weight | 1 | 2013 | 976 | 0.020 |
Why?
| | Thiocarbamates | 1 | 2008 | 6 | 0.020 |
Why?
| | Collagen | 1 | 2011 | 456 | 0.020 |
Why?
| | Chromones | 1 | 2008 | 42 | 0.020 |
Why?
| | Adoptive Transfer | 1 | 2009 | 198 | 0.020 |
Why?
| | Patient Acceptance of Health Care | 1 | 2015 | 885 | 0.020 |
Why?
| | Liver Diseases | 1 | 2011 | 304 | 0.020 |
Why?
| | GTP Cyclohydrolase | 1 | 2008 | 10 | 0.020 |
Why?
| | Benzylamines | 1 | 2008 | 43 | 0.020 |
Why?
| | Cyclic N-Oxides | 1 | 2008 | 33 | 0.020 |
Why?
| | Amidines | 1 | 2008 | 15 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2009 | 370 | 0.020 |
Why?
| | CX3C Chemokine Receptor 1 | 1 | 2007 | 19 | 0.020 |
Why?
| | Antimycin A | 1 | 2007 | 14 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2013 | 1985 | 0.020 |
Why?
| | Proline | 1 | 2008 | 83 | 0.020 |
Why?
| | Cell Count | 1 | 2008 | 320 | 0.020 |
Why?
| | Spin Labels | 1 | 2008 | 59 | 0.020 |
Why?
| | Antibodies, Anti-Idiotypic | 1 | 2007 | 51 | 0.020 |
Why?
| | Morpholines | 1 | 2008 | 128 | 0.020 |
Why?
| | Renal Circulation | 1 | 2008 | 75 | 0.020 |
Why?
| | Health Promotion | 1 | 2014 | 774 | 0.020 |
Why?
| | Rats, Inbred Strains | 1 | 2007 | 321 | 0.020 |
Why?
| | von Willebrand Factor | 1 | 2007 | 85 | 0.020 |
Why?
| | Attitude of Health Personnel | 1 | 2015 | 1185 | 0.020 |
Why?
| | RNA, Catalytic | 1 | 2007 | 189 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2008 | 310 | 0.020 |
Why?
| | Acrylates | 1 | 2006 | 48 | 0.010 |
Why?
| | Cysteine Endopeptidases | 1 | 2006 | 73 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2012 | 1125 | 0.010 |
Why?
| | Sex Characteristics | 1 | 2011 | 790 | 0.010 |
Why?
| | Killer Cells, Natural | 1 | 2009 | 467 | 0.010 |
Why?
| | Acute Disease | 1 | 2008 | 1030 | 0.010 |
Why?
| | Cathepsin B | 1 | 2005 | 16 | 0.010 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2007 | 297 | 0.010 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2005 | 49 | 0.010 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2006 | 186 | 0.010 |
Why?
| | Caspase 7 | 1 | 2005 | 22 | 0.010 |
Why?
| | Inhibitory Concentration 50 | 1 | 2005 | 91 | 0.010 |
Why?
| | Fas Ligand Protein | 1 | 2005 | 60 | 0.010 |
Why?
| | Cell Survival | 1 | 2008 | 1098 | 0.010 |
Why?
| | Thermosensing | 1 | 2004 | 12 | 0.010 |
Why?
| | Kidney Cortex | 1 | 2004 | 27 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2013 | 3409 | 0.010 |
Why?
| | DNA Fragmentation | 1 | 2004 | 39 | 0.010 |
Why?
| | Sialoglycoproteins | 1 | 2005 | 158 | 0.010 |
Why?
| | Microvilli | 1 | 2004 | 75 | 0.010 |
Why?
| | Animals, Genetically Modified | 1 | 2005 | 250 | 0.010 |
Why?
| | Mitochondrial Proteins | 1 | 2006 | 262 | 0.010 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2005 | 253 | 0.010 |
Why?
| | Wounds and Injuries | 1 | 2012 | 956 | 0.010 |
Why?
| | Perfusion | 1 | 2004 | 250 | 0.010 |
Why?
| | Cell Movement | 1 | 2007 | 965 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 5868 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2005 | 496 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2006 | 737 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2007 | 2527 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2014 | 6048 | 0.010 |
Why?
| | Temperature | 1 | 2004 | 679 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2007 | 965 | 0.010 |
Why?
|
|
Faubel's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|